Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study by Bertolaccini, Luca et al.
Bertolaccini et al. Journal of Cardiothoracic Surgery 2010, 5:45
http://www.cardiothoracicsurgery.org/content/5/1/45
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Bertolaccini et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research article Lung sealant and morbidity after pleural 
decortication: a prospective randomized, blinded 
study
Luca Bertolaccini*1, Paraskevas Lybéris2 and Emilpaolo Manno3
Abstract
Objectives: Prolonged postoperative air leaks (AL) are a major cause of morbidity. Aim of this work was evaluating use 
of a Lung Sealant System (Pleuraseal™, Covidien, Mansfield, MA, U.S.A.) in pleural decortications for empyema thoracis.
Methods: From January 2008 to December 2008, 46 consecutive patients received pleural decortications for 
empyema thoracis. Post-procedural and malignancy-related empyemas were excluded. After hydro-pneumatic test 
and surgical correction of AL (until satisfaction), patients were assigned (23 per group) to Control or Sealant group. 
Control group underwent no additional interventions. In Sealant group, lung sealant was applied over AL areas. 
Following variables were measured daily: patients with AL; time to chest drainage (CD) removal; CD drainage volume at 
removal, postoperative length of hospital stay, postoperative C-reactive protein (CRP), and leukocyte counts. Personnel 
recording parameters were blinded to intervention. Two-tailed t-tests (normally distributed data) or Mann - Whitney U-
test (not-normally distributed data) were used for evaluating significance of differences between group means or 
medians. Significance of any proportional differences in attributes were evaluated using Fisher's Exact Test. Statistical 
analysis was carried out using R-software (version 2.8.1).
Results: Groups were similar regarding demographic and baseline characteristics. No patients were withdrawn from 
study; no adverse effects were recorded. There were no significative differences on CRP and leukocyte levels between 
two groups. Compared with the Control group, in Sealant group significantly fewer patients had AL (30 versus 78%, p = 
0.012), and drains were inserted for a shorter time (medians, 3 versus 5 days, p = 0.05). Postoperative hospitalization time 
was shorter in Sealant group than in control group, but difference was not significant (0.7 days, p = 0.121).
Conclusions: Pleuraseal™ Lung Sealant System significantly reduces AL following pleural decortications for empyema 
and, despite of not-increased infectious indexes, is suitable for routinely use, even in procedures with contaminated 
pleura.
Introduction
Prolonged parenchymal air leak is the most common
complication after lung resection [1]. Prolonged air leak
lead to prolonged chest tube drainage time, associated
with pain and immobilization that puts the patients at an
increased risk for development of infections and bronco-
pleural fistulae and, consequently, a prolonged hospital
stay, which increases healthcare costs [2]. A variety of
complementary natural and synthetic materials have
been tried to overcome such complications including
fibrin sealants, collagen fleece, and synthetic glues [3].
Nevertheless, they can be very helpful in situations where
air leakage cannot be assured by classic means [4]. Addi-
tional techniques included the application of a number of
products such as fibrin glue [5-7], synthetic sealants [8-
10] and fleece bound sealants [11]. However, major criti-
cisms elicited by currently available studies include lack
of a precise methodology, usually limited numerosity, and
presence of significant confounding factors (i.e. postoper-
ative air leak assessment) [12,13]. Empyema thoracis
remains a significant cause of morbidity and even mortal-
ity in modern thoracic practice [14]. In surgical decorti-
cation, the risk of air leak was increased, but most of
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sealant cannot be use in infected pleural space [15]. We
have tested the application of a lung synthetic sealant to
evaluate the safety and efficacy of this surgical sealant for
the treatment of parenchymal air leaks occurring after
pleural decortication within the setting of a prospective
randomized blinded trial.
Materials and methods
This prospective randomized blinded study was carried
out between January 2008 and December 2008. Forty-six
consecutive adult patients with pleural empyema that
received pleural decortication for empyema thoracis were
enrolled. Post-procedural and malignancy-related empy-
emas were excluded. Three skilled Thoracic Surgeons
carried out pleural decortication using standard tech-
niques. At the end of the operation, before closing the
chest, the lung was ventilated under positive-end expira-
tory pressure and warm saline was installed into the chest
cavity to test air leaks. The operating surgeon corrected
any leaks surgically, until satisfied. The patients were,
then, assigned (23 per group) to either the Control Group
or Sealant Group by opening a sealed envelope that con-
tained the randomization code (allocated by a computer
generated random sequence, http://www.random.org/
premium/?mode=advanced). Patients assigned to the
Control Group underwent no additional interventions. In
patients assigned to the Sealant Group, lung sealant
(Pleuraseal™, Covidien, Mansfield MA, U.S.A.) was
applied over the entire areas of air leaks with the lung
partially inflated (65 - 75%). After the application, the
lung was completely ventilated and the chest closed with
two thoracic drains (32 F) set at suction at -20 cm H2O.
Following variables were measured and recorded daily,
until discharged from hospital: rate of air leakage on the
day of the operation, daily rate of air leak until removal of
chest drains; time to chest drainage removal; chest drain-
age volume (bleeding/exudation) at removal of chest
tube, postoperative length of hospital stay, postoperative
C-reactive protein, and leukocyte counts. The rate of air
leakage was assessed by a mechanical suction pump
(Drentech P.A.L.M., Redax S.r.l., Mirandola (MO), Italy)
and was expressed in liters per hour. Personnel recording
parameters were blinded to the group assignment.
Adverse events were monitored throughout the patients
hospital stay. Postoperative air leakage, chest tube drain-
age and hospitalization time were used as indicators of
postoperative morbidity.
D a t a  f o r  e a c h  v a r i a b l e  a n d  w i t h i n  e a c h  r a n d o m i z e d
group were tested for significant deviation from a normal
distribution using the Kolmogorov-Smirnov test for a
given cumulative distribution function F(x) (defined as
 where   is the indicator
function, equal to 1 if Xi ≤ x and equal to 0 otherwise).
Two-tailed t-tests (normally distributed data) or Wil-
coxon-Mann-Whitney U-test (non-normally distributed
data) were used for evaluating the significance of differ-
ences between group means or medians, as appropriate.
The significance of any proportional differences in attri-
butes (e.g. air leakage present or absent) were evaluated
using the Fisher's Exact Test (two groups). Statistical
analysis was carried out using R-software (version 2.8.1),
a free software environment for statistical computing and
g r a p h i c s  t h a t  c o m p i l e s  a n d  r u n s  o n  a  w i d e  v a r i e t y  o f
UNIX platforms, Windows and MacOS http://www.r-
project.org/.
Results
B o t h  g r o u p s  w e r e  s i m i l a r  w i t h  r e g a r d  t o  d e m o g r a p h i c
and baseline characteristics (Table 1). The mean age for
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Table 1: Demographic and baseline characteristics.
Variable Sealant Group Control Group p value
Age: years ± SD 53 (12) 55 (10) 0.68
Male: n (%) 11 (48%) 12 (52%) 0.55
Female: n (%) 9 (39%) 14 (61%) 0.63
Smokers: n (%) 18 (78%) 16 (70%) 1.00
Predicted FEV1: % ± SD 76 (19) 85 (18) 0.09
Predicted CO-diff: % ± SD 76 (10) 81 (21) 0.31
FEV1: forced expiratory volume in one second; CO-diff: carbon monoxide difference.Bertolaccini et al. Journal of Cardiothoracic Surgery 2010, 5:45
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the total study population was 54 years (standard devia-
tion: 11 years). Thirty-four patients (73.9%) were smok-
ers. There was no statistical significant difference with
regard to their forced expiratory flow in one second
(FEV1). Patients' general conditions were considered nor-
mal risks for decortication for empyema thoracis. No
patients with bullous disease or emphysema were found.
No patients were withdrawn from the study and no
adverse effects were recorded during the study. Results
for each of the performance variables for both random-
ized groups are summarized in Table 2. Sealant Group
was associated with a mean lower total drainage volume
compared with the Control Group (534 ml ± 149 ml vs.
873 ml ± 257 ml). This difference was highly statistically
significant (p < 0.001). Number of patients without post-
operative air leak was significantly greater (7 patients,
30%) in the Sealant Group compared to the Control
Group (18 patients, 78%), p < 0.012. Although median
durations of chest drainage and hospitalization times
were shorter in the Sealant Group compared with Con-
trol Groups (3 days ( quartiles 1.5) vs. 5 days (quartiles
1.4), p < 0.05), the postoperative hospitalization were not
statistically significant (4 days (quartiles 4.5) vs. 4.5 days
(quartiles 4.7), p < 0.121). Postoperative leukocyte levels
were similar in both groups (10.9 103 g/l ± 3.2 103 g/l vs.
10.7 103 g/l ± 3.1 103 g/l, p < 0.95). Postoperative C Reac-
tive Protein levels were not statistically different between
two groups (11.3 g/l ± 2.3 g/l vs. 10.9 g/l ± 1.7 g/l, p <
0.97).
Discussion
Intra-operative air leaks after standard pleural decortica-
tion are reported ranging between 48% and 70% in main
series [16,17]. For this reason, increasing requirements
for new sealant products has stimulated active industrial
research and clinical experimentation. Recently, a meta-
analysis has showed the absence of a definitive advantage
from using sealants in pulmonary surgery when the end-
points are the reduction of in-hospital length of stay and
postoperative morbidity [17]. Current clinical experimen-
tation in this field has indicated that sealant materials
have to display a number of characteristics. They need to
be adherent to pressure of inflated lung, but also elastic
and unaltered by intrapleural fluids; they also need to be
non-irritating, systematically non-toxic, and without
antigenicity [12]. Pleuraseal™ (Covidien, Mansfield MA,
U.S.A.) sealant, whose basic mechanism is the rapid for-
mation of a biocompatible hydro-gel that firmly adheres
to the tissue, has many of these characteristics. Applica-
tion of this sealant has allowed significant reduction of
proportion of patients showing post-operative air leaks.
Furthermore, among the patients who received sealant
therapy but showed postoperative air leaks, the duration
of air leaks was significantly shorter, if compared with the
standard care group. Despite the clinical advantage
obtained by the earlier air leak cessation, a statistically
significant reduction in the duration of the hospital stay
was not found in patients receiving sealant application;
although they showed a favorable trend towards shorter
hospitalization, (air leakage is not the only major reason
Table 2: Results.
Variable Sealant Group Control Group p value
Patients (%) with air leak 7 (30%) 18 (78%) 0.012
Total drainage volume (ml): 
mean ± SD
534 ± 149 873 ± 257 <0.001
Days with drain: median 
(quartiles)
3 (1.5) 5 (1.4) 0.05 *
Postoperative hospitalization 
(days): median (quartiles)
4 (4.5) 4.5 (4.7) 0.121 *
Postoperative leukocyte level 
(103 g/l) ± SD
10.9 ± 3.2 10.7 ± 3.1 0.95
Postoperative C-reactive 
protein level (g/l) ± SD
11.3 ± 2.3 10.9 ± 1.7 0.97
SD, standard deviation.
* Data was not normally distributed and was analyzed by non-parametric statistics (Wilcoxon-Mann-Whitney U-test; exact significance 
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for postoperative hospitalization). We have not observed
any specific complication related to the use of the sealant
and postoperative morbidity was similar in the two
groups. In particular, we do not found increase in the
postoperative levels of leukocyte and CRP in the Sealant
Group.
The application of Pleuraseal™ sealant in this random-
ized study proved safe and effective in reducing air leaks
occurring after pleural decortications for empyema tho-
racis, in shortening the duration of air leak with a trend
towards a shorter postoperative hospital stay, and despite
of not-increased infectious indexes, is suitable for rou-
tinely use, even in procedures with contaminated pleura.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LB conceived of the study in Maria Vittoria Hospital (where worked, as Consul-
tant, until 2009), performed the statistical analysis and participated in design
and coordination of the study. PL participated in data collection. EM partici-
pated in design and coordination of the study. All authors read and approved
the final manuscript.
Author Details
1Thoracic Surgery Unit, S. Croce Hospital, Cuneo, Italy, 2Division of General 
Surgery, Maria Vittoria Hospital, Turin, Italy and 3Intensive Care Unit, Maria 
Vittoria Hospital, Turin, Italy
References
1. Belboul RA, Dernevik L, Aljassim O, Skrbic B, Rådberg G, Roberts D: The 
effect of autologous fibrin sealant (Vivostat®) on morbidity after 
pulmonary lobectomy: a prospective randomised, blinded study.  Eur J 
Cardiothorac Surg 2004, 26:1187-1191.
2. D'Andrilli A, Andreetti C, Ibrahim M, Ciccone AM, Venuta F, Mansmann U, 
Rendina EA: A prospective randomized study to assess the efficacy of a 
surgical sealant to treat air leaks in lung surgery.  Eur J Cardiothorac Surg 
2009, 35:817-821.
3. Brunelli A, Monteverde M, Borri A, Salati M, Marasco RD, Fianchini A: 
Predictors of prolonged air leak after pulmonary lobectomy.  Ann 
Thorac Surg 2004, 77:1205-10.
4. Varela G, Jimenez MF, Novoa N, Aranda JL: Estimating hospital costs 
attributable to prolonged air leak in pulmonary lobectomy.  Eur J 
Cardiothorac Surg 2005, 27:329-33.
5. Wong K, Goldstraw P: Effect of fibrin glue in the reduction of 
postthoracotomy alveolar air leak.  Ann Thorac Surg 1997, 64:979-81.
6. Fleisher AG, Evans KG, Nelems B, Finley RJ: Effect of routine fibrin glue 
use on the duration of air leaks after lobectomy.  Ann Thorac Surg 1990, 
49:133-4.
7. Fabian T, Federico JA, Ponn RB: Fibrin glue in pulmonary resection: a 
prospective, randomized, blinded study.  Ann Thorac Surg 2003, 
75:1587-92.
8. Porte HL, Jany T, Akkad R, Conti M, Gillet PA, Guidat A, Wurtz AJ: 
Randomized controlled trial of a synthetic sealant for preventing 
alveolar air leaks after lobectomy.  Ann Thorac Surg 2001, 71:1618-22.
9. Wain JC, Kaiser LR, Johnstone DW, Yang SC, Wright CD, Friedberg JS, Feins 
RH, Heitmiller RF, Mathisen DJ, Selwyn MR: Trial of a novel synthetic 
sealant in preventing air leaks after lung resection.  Ann Thorac Surg 
2001, 71:1623-8.
10. Macchiarini P, Wain J, Almy S, Dartevelle P: Experimental and clinical 
evaluation of a new synthetic, absorbable sealant to reduce air leaks in 
thoracic operations.  J Thorac Cardiovasc Surg 1999, 117:751-8.
11. Lang G, Csekeö A, Stamatis G, Lampl L, Hagman L, Marta GM, Mueller MR, 
Klepetko W: Efficacy and safety of topical application of human 
fibrinogen/thrombin-coated collagen patch (TachoComb) for 
treatment of air leakage after standard lobectomy.  Eur J Cardiothorac 
Surg 2004, 25:160-6.
12. Serra-Mitjans M, Belda-Sanchis J, Rami-Porta R: Surgical sealant for 
preventing air leaks after pulmonary resections in patients with lung 
cancer.  Cochrane Database of Systematic Reviews 2005:CD003051. 
doi:10.1002/14651858
13. Rocco G, Rendina EA, Venuta F, Mueller MR, Halezeroglu S, Hendrik H, Van 
Raemdonck D, Hansen HJ: The use of sealants in modern thoracic 
surgery: a survey.  Interac CardioVasc Thorac Surg 2009, 9:1-3.
14. Chan DTL, Sihoe ADL, Chan S, Tsang DSF, Fang B, Lee TW, Cheng LC: 
Surgical Treatment for Empyema Thoracis: Is Video-Assisted Thoracic 
Surgery "Better" Than Thoracotomy?  Ann Thorac Surg 2007, 84:225-231.
15. Wain JC, Kaiser LR, Johnstone DW, Yang SC, Wright CD, Friedberg JS, Feins 
RH, Heitmiller RF, Mathisen DJ, Selwyn MR: Trial of a novel synthetic 
sealant in preventing air leaks after lung resection.  Ann Thorac Surg 
2001, 71:1623-8.
16. Lang G, Csekeö A, Stamatis G, Lampl L, Hagman L, Marta GM, Mueller MR, 
Klepetko W: Efficacy and safety of topical application of human 
fibrinogen/thrombin-coated collagen patch (TachoComb) for 
treatment of air leakage after standard lobectomy.  Eur J Cardiothorac 
Surg 2004, 25:160-6.
17. Marta GM, Facciolo F, Ladegaard L, Dienemann H, Csekeo A, Rea F, Passlick 
B, Spaggiari L, Tetens V, Klepetko W: Tachosil vs. standard surgical 
treatment for air leakage in pulmonary lobectomy.  Interact CardioVasc 
Thorac Surg 2008, 7:S147-S200.
doi: 10.1186/1749-8090-5-45
Cite this article as: Bertolaccini et al., Lung sealant and morbidity after pleu-
ral decortication: a prospective randomized, blinded study Journal of Cardio-
thoracic Surgery 2010, 5:45
Received: 5 November 2009 Accepted: 28 May 2010 
Published: 28 May 2010
This article is available from: http://www.cardiothoracicsurgery.org/content/5/1/45 © 2010 Bertolaccini et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Cardiothoracic Surgery 2010, 5:45